The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Hormonal Therapy for Prostate Cancer
Open accessAbstract
Huggins and Hodges demonstrated the therapeutic effect of gonadal testosterone deprivation in the 1940s and therefore firmly established the concept that prostate cancer is a highly androgen-dependent disease. Since that time, hormonal therapy has undergone iterative advancement, from the types of gonadal testosterone deprivation to modalities that block the generation of adrenal and other extragonadal androgens, to those that directly bind and inhibit the androgen receptor (AR). The clinical states of prostate cancer are the product of a superimposition of these therapies with nonmetastatic advanced prostate cancer, as well as frankly metastatic disease. Today’s standard of care for advanced prostate cancer includes gonadotropin-releasing hormone agonists (e.g., leuprolide), second-generation nonsteroidal AR antagonists (enzalutamide, apalutamide, and darolutamide) and the androgen biosynthesis inhibitor abiraterone. The purpose of this review is to provide an assessment of hormonal therapies for the various clinical states of prostate cancer. The advancement of today’s standard of care will require an accounting of an individual’s androgen physiology that also has recently recognized germline determinants of peripheral androgen metabolism, which include HSD3B1 inheritance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y.-H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y.-N., Hahn, N., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,896
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
The Influence of Finasteride on the Development of Prostate Cancer
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030660 · Cited by 2,518
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Sathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
Abiraterone for prostate cancer not previously treated with hormone therapy
James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903835 · Cited by 1,633
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903307 · Cited by 1,564
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
HUGGINS, C. (1941) · Archives of Surgery · doi:10.1001/archsurg.1941.01210140043004 · Cited by 1,499
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Cornford, P., Bellmunt, J., Bolla, M., Briers, E., De Santis, M., Gross, T., Henry, A. M., Joniau, S., Lam, T. B., Mason, M. D., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.002 · Cited by 1,438
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Genomic correlates of clinical outcome in advanced prostate cancer
Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902651116 · Cited by 1,372
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715546 · Cited by 1,344
Huggins, C., & Hodges, C. V. (1972) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.22.4.232 · Cited by 1,320
Armstrong, A. J., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Azad, A., Alcaraz, A., Alekseev, B., Iguchi, T., Shore, N. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00799 · Cited by 1,217
Effect of Dutasteride on the Risk of Prostate Cancer
Andriole, G. L., Bostwick, D. G., Brawley, O. W., Gomella, L. G., Marberger, M., Montorsi, F., Pettaway, C. A., Tammela, T. L., Teloken, C., Tindall, D. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908127 · Cited by 1,152
Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence
Matsuo, H., Baba, Y., Nair, R. M. G., Arimura, A., & Schally, A. V. (1971) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(71)80019-0 · Cited by 1,135
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800536 · Cited by 1,035
Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence
(1976) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(76)90821-8 · Cited by 1,033
The Conversion of Testosterone to 5α-Androstan-17β-ol-3-one by Rat Prostate in Vivo and in Vitro
Bruchovsky, N., & Wilson, J. D. (1968) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)93542-8 · Cited by 1,026
Eiber, M., Maurer, T., Souvatzoglou, M., Beer, A. J., Ruffani, A., Haller, B., Graner, F.-P., Kübler, H., Haberhorn, U., Eisenhut, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154153 · Cited by 994
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Arora, V. K., Schenkein, E., Murali, R., Subudhi, S. K., Wongvipat, J., Balbas, M. D., Shah, N., Cai, L., Efstathiou, E., Logothetis, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.012 · Cited by 986
Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 950
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815671 · Cited by 930
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Kantoff, P. W., Halabi, S., Conaway, M., Picus, J., Kirshner, J., Hars, V., Trump, D., Winer, E. P., & Vogelzang, N. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2506 · Cited by 890
Kirby, M., Hirst, C., & Crawford, E. D. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02799.x · Cited by 861
Glucocorticoid receptor signaling in health and disease
Kadmiel, M., & Cidlowski, J. A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.07.003 · Cited by 849
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
(2000) · The Lancet · doi:10.1016/s0140-6736(00)02163-2 · Cited by 819
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747
Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70560-0 · Cited by 744
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.039 · Cited by 733
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., Cai, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3948 · Cited by 662
Klotz, L. H., BOCCON-GIBOD, L., Shore, N. D., Andreou, C., Persson, B., Cantor, P., Jensen, J.-K., Olesen, T. K., & Schröder, F. H. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.08183.x · Cited by 614
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577
Kroboth, P. D., Salek, F. S., Pittenger, A. L., Fabian, T. J., & Frye, R. F. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922007903 · Cited by 518
Smith, M. R., Kabbinavar, F., Saad, F., Hussain, A., Gittelman, M. C., Bilhartz, D. L., Wynne, C., Murray, R., Zinner, N. R., Schulman, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.529 · Cited by 496
Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer
Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B., & Mohler, J. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0525 · Cited by 488
Azad, A. A., Volik, S. V., Wyatt, A. W., Haegert, A., Le Bihan, S., Bell, R. H., Anderson, S. A., McConeghy, B., Shukin, R., Bazov, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2666 · Cited by 478
Gonadotropin-releasing hormone and its analogues
Desforges, J. F., Conn, P. M., & Crowley, W. F. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101103240205 · Cited by 470
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Shore, N. D., Saad, F., Cookson, M. S., George, D. J., Saltzstein, D. R., Tutrone, R., Akaza, H., Bossi, A., van Veenhuyzen, D. F., Selby, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004325 · Cited by 444
Plasma AR and abiraterone-resistant prostate cancer
Romanel, A., Tandefelt, D. G., Conteduca, V., Jayaram, A., Casiraghi, N., Wetterskog, D., Salvi, S., Amadori, D., Zafeiriou, Z., Rescigno, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9511 · Cited by 441
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
Xie, W., Regan, M. M., Buyse, M., Halabi, S., Kantoff, P. W., Sartor, O., Soule, H., Clarke, N. W., Collette, L., Dignam, J. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.9987 · Cited by 433
Amoss, M., Burgus, R., Blackwell, R., Vale, W., Fellows, R., & Guillemin, R. (1971) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(71)80179-1 · Cited by 430
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Sternberg, C. N., Fizazi, K., Saad, F., Shore, N. D., De Giorgi, U., Penson, D. F., Ferreira, U., Efstathiou, E., Madziarska, K., Kolinsky, M. P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003892 · Cited by 428
Ketoconazole Blocks Adrenal Steroid Synthesis
PONT, A., WILLIAMS, P. L., LOOSE, D. S., FELDMAN, D., REITZ, R. E., BOCHRA, C., & STEVENS, D. A. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-3-370 · Cited by 422
Gonadotropin-Releasing Hormone and Its Analogues
Kovacs, P. (2020) · Textbook of Assisted Reproduction · doi:10.1007/978-981-15-2377-9_8 · Cited by 422
Androgen Signaling in Prostate Cancer
Dai, C., Heemers, H., & Sharifi, N. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030452 · Cited by 406
Self-citationRyan, C. J., Smith, M. R., Fong, L., Rosenberg, J. E., Kantoff, P., Raynaud, F., Martins, V., Lee, G., Kheoh, T., Kim, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1281 · Cited by 396
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Sharp, A., Coleman, I., Yuan, W., Sprenger, C., Dolling, D., Rodrigues, D. N., Russo, J. W., Figueiredo, I., Bertan, C., Seed, G., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122819 · Cited by 393
Neural Control of the Pituitary Gland.—I
Harris, G. W. (1951) · BMJ · doi:10.1136/bmj.2.4731.559 · Cited by 381
Moilanen, A.-M., Riikonen, R., Oksala, R., Ravanti, L., Aho, E., Wohlfahrt, G., Nykänen, P. S., Törmäkangas, O. P., Palvimo, J. J., & Kallio, P. J. (2015) · Scientific Reports · doi:10.1038/srep12007 · Cited by 379
Wyatt, A. W., Azad, A. A., Volik, S. V., Annala, M., Beja, K., McConeghy, B., Haegert, A., Warner, E. W., Mo, F., Brahmbhatt, S., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0494 · Cited by 373
Armstrong, A. J., Halabi, S., Luo, J., Nanus, D. M., Giannakakou, P., Szmulewitz, R. Z., Danila, D. C., Healy, P., Anand, M., Rothwell, C. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01731 · Cited by 362
Screening for Prostate Cancer With the Prostate-Specific Antigen Test: A Review of Current Evidence
Hayes, J. H., & Barry, M. J. (2014) · JAMA · doi:10.1001/jama.2014.2085 · Cited by 361
Ketoconazole blocks testosterone synthesis
Pont, A. (1982) · Archives of Internal Medicine · doi:10.1001/archinte.142.12.2137 · Cited by 350
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
Chang, K.-H., Li, R., Papari-Zareei, M., Watumull, L., Zhao, Y. D., Auchus, R. J., & Sharifi, N. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107898108 · Cited by 346
Self-citationCardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist
Albertsen, P. C., Klotz, L., Tombal, B., Grady, J., Olesen, T. K., & Nilsson, J. (2014) · European Urology · doi:10.1016/j.eururo.2013.10.032 · Cited by 341
The hypothalamus-pituitary-gonad axis: Tales of mice and men
Kaprara, A., & Huhtaniemi, I. T. (2018) · Metabolism · doi:10.1016/j.metabol.2017.11.018 · Cited by 329
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
Penson, D. F., Armstrong, A. J., Concepcion, R., Agarwal, N., Olsson, C., Karsh, L., Dunshee, C., Wang, F., Wu, K., Krivoshik, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.9285 · Cited by 319
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Chang, K.-H., Li, R., Kuri, B., Lotan, Y., Roehrborn, C. G., Liu, J., Vessella, R., Nelson, P. S., Kapur, P., Guo, X., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.029 · Cited by 312
Self-citationNeural Control of the Pituitary Gland
(1956) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1956.tb56918.x · Cited by 305
Ketoconazole Blocks Testosterone Synthesis
Pont, A. (1982) · Archives of Internal Medicine · doi:10.1001/archinte.1982.00340250097015 · Cited by 296
60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-pituitary–gonadal axis
Plant, T. M. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0113 · Cited by 289
Attard, G., Reid, A. H. M., Auchus, R. J., Hughes, B. A., Cassidy, A. M., Thompson, E., Oommen, N. B., Folkerd, E., Dowsett, M., Arlt, W., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2189 · Cited by 282
Shore, N. D., Chowdhury, S., Villers, A., Klotz, L., Siemens, D. R., Phung, D., van Os, S., Hasabou, N., Wang, F., Bhattacharya, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00518-5 · Cited by 278
Isikbay, M., Otto, K., Kregel, S., Kach, J., Cai, Y., Vander Griend, D. J., Conzen, S. D., & Szmulewitz, R. Z. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0173-2 · Cited by 274
Systematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells
Östling, P., Leivonen, S.-K., Aakula, A., Kohonen, P., Mäkelä, R., Hagman, Z., Edsjö, A., Kangaspeska, S., Edgren, H., Nicorici, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2421 · Cited by 270
Conteduca, V., Wetterskog, D., Sharabiani, M. T. A., Grande, E., Fernandez-Perez, M. P., Jayaram, A., Salvi, S., Castellano, D., Romanel, A., Lolli, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx155 · Cited by 269
Jung, M. E., Ouk, S., Yoo, D., Sawyers, C. L., Chen, C., Tran, C., & Wongvipat, J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901488g · Cited by 266
The Androgen Receptor in Health and Disease
Matsumoto, T., Sakari, M., Okada, M., Yokoyama, A., Takahashi, S., Kouzmenko, A., & Kato, S. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183656 · Cited by 266
Rathkopf, D. E., Morris, M. J., Fox, J. J., Danila, D. C., Slovin, S. F., Hager, J. H., Rix, P. J., Chow Maneval, E., Chen, I., Gönen, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.1684 · Cited by 261
Increasing incidence of metastatic prostate cancer in the United States (2004–2013)
Weiner, A. B., Matulewicz, R. S., Eggener, S. E., & Schaeffer, E. M. (2016) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.30 · Cited by 255
Immunotherapy of Prostate Cancer: Facts and Hopes
Bilusic, M., Madan, R. A., & Gulley, J. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0019 · Cited by 244
Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
Eiber, M., Fendler, W. P., Rowe, S. P., Calais, J., Hofman, M. S., Maurer, T., Schwarzenboeck, S. M., Kratowchil, C., Herrmann, K., & Giesel, F. L. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186767 · Cited by 241
Scher, H. I., Graf, R. P., Schreiber, N. A., Jayaram, A., Winquist, E., McLaughlin, B., Lu, D., Fleisher, M., Orr, S., Lowes, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1621 · Cited by 241
Scher, H. I., Solo, K., Valant, J., Todd, M. B., & Mehra, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139440 · Cited by 238
Clinical states in prostate cancer: toward a dynamic model of disease progression
Scher, H. I., & Heller, G. (2000) · Urology · doi:10.1016/s0090-4295(99)00471-9 · Cited by 232
Revisiting Immunotherapy: A Focus on Prostate Cancer
Cha, H.-R., Lee, J. H., & Ponnazhagan, S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2948 · Cited by 223
Marchais-Oberwinkler, S., Henn, C., Möller, G., Klein, T., Negri, M., Oster, A., Spadaro, A., Werth, R., Wetzel, M., Xu, K., et al. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.12.013 · Cited by 216
Lallous, N., Volik, S. V., Awrey, S., Leblanc, E., Tse, R., Murillo, J., Singh, K., Azad, A. A., Wyatt, A. W., LeBihan, S., et al. (2016) · Genome Biology · doi:10.1186/s13059-015-0864-1 · Cited by 208
NF-κB Regulates Androgen Receptor Expression and Prostate Cancer Growth
Zhang, L., Altuwaijri, S., Deng, F., Chen, L., Lal, P., Bhanot, U. K., Korets, R., Wenske, S., Lilja, H. G., Chang, C., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080727 · Cited by 191
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
Li, Z., Alyamani, M., Li, J., Rogacki, K., Abazeed, M., Upadhyay, S. K., Balk, S. P., Taplin, M.-E., Auchus, R. J., & Sharifi, N. (2016) · Nature · doi:10.1038/nature17954 · Cited by 171
Self-citationCai, C., Wang, H., Xu, Y., Chen, S., & Balk, S. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0395 · Cited by 169
Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer
Zhao, E., Wang, L., Dai, J., Kryczek, I., Wei, S., Vatan, L., Altuwaijri, S., Sparwasser, T. D., Wang, G., Keller, E. T., et al. (2012) · OncoImmunology · doi:10.4161/onci.1.2.18480 · Cited by 161
Hearn, J. W. D., AbuAli, G., Reichard, C. A., Reddy, C. A., Magi‐Galluzzi, C., Chang, K., Carlson, R. E., Rangel, L. J., Reagan, K., Davis, B. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30227-3 · Cited by 146
Self-citationLi, J., Alyamani, M., Zhang, A., Chang, K., Berk, M. P., Li, Z., Zhu, Z., Petro, M., Magi‐Galluzzi, C., Taplin, M., et al. (2017) · eLife · doi:10.7554/elife.20183 · Cited by 136
Self-citationAndrogen receptor splice variants and prostate cancer: From bench to bedside
Wadosky, K. M., & Koochekpour, S. (2017) · Oncotarget · doi:10.18632/oncotarget.14537 · Cited by 135
Smith, M. R., Antonarakis, E. S., Ryan, C. J., Berry, W. R., Shore, N. D., Liu, G., Alumkal, J. J., Higano, C. S., Maneval, E. C., Bandekar, R. R., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.04.023 · Cited by 134
Waxman, J., Man, A., Hendry, W. F., WHITFIELD, H. N., BESSER, G. M., Tiptaft, R. C., Paris, A. M., & Oliver, R. T. D. (1985) · BMJ · doi:10.1136/bmj.291.6506.1387 · Cited by 133
Chen, W. S., Aggarwal, R. R., Zhang, L., Zhao, S. G., THOMAS, G. V., Beer, T. M., Quigley, D. A., Foye, A., Playdle, D., Huang, J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.03.020 · Cited by 133
Jiang, Y., Palma, J. F., Agus, D. B., Wang, Y., & Gross, M. E. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.143297 · Cited by 132
LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action
Limonta, P., Marelli, M. M., & Moretti, R. M. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.4.709 · Cited by 128
DHT Concentrations in Human Prostate Cancer Tissue*
Geller, J., ALBERT, J. D., Loza, D., Geller, S., Stoeltzing, W., & DANIEL, D. L. V. (1978) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-46-3-440 · Cited by 128
Sun, M., Choueiri, T. K., Hamnvik, O. R., Preston, M. A., de Velasco, G., Jiang, W., Loeb, S., Nguyen, P. L., & Trinh, Q. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4917 · Cited by 124
Mousses, S., Wagner, U., Chen, Y., Kim, J. W., Bubendorf, L., Bittner, M. L., Pretlow, T. G., ELKAHLOUN, A. G., Trepel, J. B., & Kallioniemi, O. (2001) · Oncogene · doi:10.1038/sj.onc.1204889 · Cited by 123
The role of diethylstilbestrol in the treatment of prostate cancer
Malkowicz, S. B. (2001) · Urology · doi:10.1016/s0090-4295(01)01252-3 · Cited by 114
A Clinician’s Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III)
Crawford, E. D., Koo, P. J., Shore, N. D., Slovin, S. F., Concepcion, R. S., Freedland, S. J., Gomella, L. G., Karsh, L. I., Keane, T. E., MARONI, P. D., et al. (2018) · The Journal of Urology · doi:10.1016/j.juro.2018.05.164 · Cited by 103
Flare Associated with LHRH-Agonist Therapy.
Thompson, I. M. (2001) · Europe PMC (PubMed Central) · Cited by 96
Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer
Crawford, E. D., Stone, N. N., Yu, E. Y., Koo, P. J., Freedland, S. J., Slovin, S. F., Gomella, L. G., Berger, E. R., Keane, T. E., SIEBER, P. R., et al. (2014) · Urology · doi:10.1016/j.urology.2013.10.026 · Cited by 95
The metabolism, analysis, and targeting of steroid hormones in breast and prostate cancer
Capper, C. P., Rae, J. M., & Auchus, R. J. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0259-0 · Cited by 89
Prostate cancer treated by anti-androgens: is sexual function preserved?
Schröder, F. H., Collette, L., de Reijke, T. M., & Whelan, P. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0916 · Cited by 85
Fizazi, K. S., Smith, M. R., & TOMBAL, B. F. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.07.017 · Cited by 85
Sex hormones and prostate cancer
Auchus, R. J., & Sharifi, N. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051418-060357 · Cited by 85
Self-citationBlackard, C. E. (1975) · PubMed · Cited by 84
HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer
Hearn, J. W. D., Sweeney, C. J., Almassi, N., Reichard, C. A., Reddy, C. A., Li, H., Hobbs, B. P., Jarrard, D. F., Chen, Y., Dreicer, R., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6496 · Cited by 81
Self-citationThe role of ketoconazole in current prostate cancer care
Patel, V. G., Liaw, B. C.-H., & Oh, W. K. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0077-y · Cited by 79
Dearnaley, D. P., Saltzstein, D. R., Sylvester, J. E., Karsh, L. I., Mehlhaff, B. A., Pieczonka, C. M., Bailen, J. L., Shi, H., Ye, Z., Faessel, H. M., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.03.001 · Cited by 76
Update on male reproductive endocrinology
Clavijo, R. I., & Hsiao, W. (2018) · Translational Andrology and Urology · doi:10.21037/tau.2018.03.25 · Cited by 75
MacLean, D. B., Shi, H., Faessel, H. M., & Fred Saad, C. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2770 · Cited by 73
Wang, L. G., Johnson, E. M., Kinoshita, Y., Babb, J. S., Buckley, M. T., Liebes, L., Melamed, J., Liu, X., Kurek, R., Ossowski, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6017 · Cited by 73
Bessone, F., Lucena, M., Roma, M. G., Stephens, C. M., Medina‐Cáliz, I., Frider, B., Tsariktsian, G., Hernández, N., Bruguera, M., Gualano, G., et al. (2015) · Liver International · doi:10.1111/liv.12899 · Cited by 67
Shiota, M., Narita, S., Akamatsu, S., Fujimoto, N., Sumiyoshi, T., Fujiwara, M., Uchiumi, T., Habuchi, T., Ogawa, O., & Eto, M. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.0115 · Cited by 66
Hearn, J. W. D., Xie, W., Nakabayashi, M., Almassi, N., Reichard, C. A., Pomerantz, M. M., Kantoff, P. W., & Sharifi, N. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3164 · Cited by 65
Self-citationAgarwal, N., Hahn, A. W., Gill, D. M., Farnham, J. M., Poole, A., & Cannon‐Albright, L. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0147 · Cited by 64
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer
Alyamani, M., Emamekhoo, H., Park, S., Taylor, J., Almassi, N., Upadhyay, S., Tyler, A. J., Berk, M. P., Hu, B., Hwang, T. H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98319 · Cited by 60
Self-citationHSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer
Almassi, N., Reichard, C. A., Li, J., Russell, C., Perry, J., Ryan, C. J., Friedlander, T. W., & Sharifi, N. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3159 · Cited by 59
Self-citationDebruyne, F. M. J., Bhat, G., & Garnick, M. B. (2006) · Future Oncology · doi:10.2217/14796694.2.6.677 · Cited by 57
Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT
Beheshti, M., Rezaee, A., Geinitz, H., Loidl, W. C., Pirich, C., & Langsteger, W. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.169730 · Cited by 57
Sabharwal, N., & Sharifi, N. (2019) · Endocrinology · doi:10.1210/en.2019-00366 · Cited by 55
Self-citationDavidsson, S., Andrén, O., Ohlson, A., Carlsson, J., Andersson, S., Giunchi, F., Rider, J. R., & Fiorentino, M. (2017) · The Prostate · doi:10.1002/pros.23442 · Cited by 51
Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities
Alyamani, M., Li, Z., Berk, M. P., Li, J., Tang, J., Upadhyay, S. K., Auchus, R. J., & Sharifi, N. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.05.020 · Cited by 50
Self-citationBiochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists
Tan, O., & Bükülmez, O. (2011) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328348a3ce · Cited by 49
Khalaf, D. J., Aragón, I. M., Annala, M., Lozano, R., Taavitsainen, S., Lorente, D., Finch, D. L., Romero-Laorden, N., Vergidis, J., Cendón, Y., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.006 · Cited by 49
Ledet, E. M., Lilly, M. B., Sonpavde, G., Lin, E., Nussenzveig, R. H., Barata, P. C., Yandell, M. D., Nagy, R. J., Kiedrowski, L. A., Agarwal, N., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0115 · Cited by 48
Dalela, D., Sun, M., Díaz, M., Karabon, P., Seisen, T., Trinh, Q., Menon, M., & Abdollah, F. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.04.012 · Cited by 46
Lu, C., Terbuch, A., Dolling, D. I., Yu, J., Wang, H., Chen, Y., Fountain, J., Bertan, C. M., Sharp, A., Carreira, S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.473 · Cited by 46
Through the Looking-Glass: Reevaluating DHEA Metabolism Through HSD3B1 Genetics
Naelitz, B. D., & Sharifi, N. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.05.006 · Cited by 45
Self-citationFink, G. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0130 · Cited by 44
Thomas, J. L., Mack, V. L., Glow, J. A., Moshkelani, D., Terrell, J. R., & Bucholtz, K. M. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.04.007 · Cited by 43
Dai, C. S., Chung, Y.-M., Kovac, E. Z., Zhu, Z., Li, J., Magi‐Galluzzi, C., Stephenson, A. J., Klein, E. A., & Sharifi, N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1313 · Cited by 43
Self-citationMetastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment
Hahn, A. W., Higano, C. S., Taplin, M., Ryan, C. J., & Agarwal, N. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200967 · Cited by 43
Case Report: Fatal Fulminant Hepatic Failure due to Cyproterone Acetate
Friedman, G., Lamoureux, E., & Sherker, A. H. (1999) · Digestive Diseases and Sciences · doi:10.1023/a:1026639432428 · Cited by 42
Zhu, Z., Chung, Y., Sergeeva, O., Kepe, V., Berk, M. P., Li, J., Ko, H., Li, Z., Petro, M., DiFilippo, F. P., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004846 · Cited by 42
Self-citationImmune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
de Almeida, D. V. P., Fong, L. H., Rettig, M. B., & Autio, K. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_278853 · Cited by 40
Steroid Receptors Aplenty in Prostate Cancer
Sharifi, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmcibr1315706 · Cited by 36
Self-citationMetastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape
Kinsey, E. N., Zhang, T., & Armstrong, A. J. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000418 · Cited by 35
Germline HSD3B1 Genetics and Prostate Cancer Outcomes
Thomas, L. J., & Sharifi, N. (2020) · Urology · doi:10.1016/j.urology.2020.08.028 · Cited by 35
Self-citationFred Saad, C., Bailen, J. L., Pieczonka, C. M., Saltzstein, D. R., SIEBER, P. R., MacLean, D. B., Shi, H., Faessel, H. M., & Shore, N. D. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.2_suppl.200 · Cited by 30
Crawford, E. D., Stanton, W. N., & Mandair, D. (2020) · Cancer Management and Research · doi:10.2147/cmar.s227583 · Cited by 29
Quality of Life with Advanced Metastatic Prostate Cancer
Resnick, M. J., & Penson, D. F. (2012) · Urologic Clinics of North America · doi:10.1016/j.ucl.2012.07.007 · Cited by 28
Alyamani, M., Li, J., Patel, M., Taylor, S., Nakamura, F., Berk, M. P., Przybycin, C. G., Posadas, E. M., Madan, R. A., Gulley, J. L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.12.002 · Cited by 28
Self-citationProstate cancer—from steroid transformations to clinical translation
Chang, K., & Sharifi, N. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.175 · Cited by 23
Self-citationSmith, M. R., Mehra, M., Nair, S. C., Lawson, J., & Small, E. J. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.10.030 · Cited by 22
Apalutamide and Metastasis-free Survival in Prostate Cancer
Smith, M. R., Yu, M. K., & Small, E. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1806189 · Cited by 19
Sharifi, N. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.009 · Cited by 9
Self-citation
Cited by
Zafar, A., Khatoon, S., Khan, M. J., Abu, J., & Naeem, A. (2025) · Discover Oncology · doi:10.1007/s12672-025-02198-8 · Cited by 565
The present and future of the Cancer Dependency Map
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C., & Vazquez, F. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00763-x · Cited by 454
Sex hormone signaling and regulation of immune function
Hoffmann, J. P., Liu, J. A., Seddu, K., & Klein, S. L. (2023) · Immunity · doi:10.1016/j.immuni.2023.10.008 · Cited by 344
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Gu, Y., Yang, R., Zhang, Y., Guo, M., Takehiro, K., Zhan, M., Yang, L., & Wang, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00239-2 · Cited by 184
Metadata
- Authors
- Desai, K., McManus, J. M., & Sharifi, N.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2021-01-22
- Volume
- 42
- Issue
- 3
- Pages
- 354-373
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W3125504885
- Cited by
- 447
- References
- 167
- FWCI
- 34.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.